Quick Summary
- First-quarter adjusted EPS reached $0.32, surpassing analyst projections of $0.26–$0.31
- Quarterly revenue totaled $3.91 billion, marking a 4.5% year-over-year increase and exceeding the $3.84 billion forecast
- Skin Health and Beauty division drove performance with 8.4% sales growth
- Kimberly-Clark’s $40 billion takeover remains scheduled for completion in H2 2026
- Company declined to issue forward guidance citing the ongoing acquisition process
Kenvue (KVUE) delivered first-quarter financial performance on Thursday that exceeded Wall Street projections for both earnings and sales, sending shares higher by approximately 1.78% during trading.
The consumer healthcare firm reported adjusted profit of $0.32 per share, outperforming the analyst consensus range of roughly $0.26 to $0.31. Quarterly sales totaled $3.91 billion for the period concluded March 29, representing a 4.5% increase from $3.74 billion recorded in the corresponding quarter of the prior year, and exceeding the anticipated $3.84 billion.
Organic revenue advanced 0.7%, supported by 1.0% positive pricing impact, though partially dampened by a 0.3% decrease in volume.
KVUE shares had declined 0.11% during pre-market activity before the announcement, though the strong performance helped restore investor confidence.
Chief Executive Officer Kirk Perry highlighted that the organization achieved net and organic revenue expansion for the second straight quarter, accompanied by year-over-year enhancements in gross margin, operating margin, and earnings per share.
Adjusted gross profit margin widened by 80 basis points to 60.8%, demonstrating supply chain improvements and beneficial pricing strategies that counterbalanced inflationary pressures and tariff-related challenges. Adjusted operating income margin climbed to 24.0% compared to 19.8% in the previous year.
Skin Health and Beauty Division Delivers Outstanding Growth
The Skin Health and Beauty category emerged as the top performer, posting net sales growth of 8.4% to reach $1.06 billion. Popular brands including Neutrogena and Aveeno experienced strong consumer demand worldwide.
Self Care increased 1.9% while Essential Health advanced 4.9%. The Self Care segment faced headwinds from a mild cold and flu season throughout key geographic regions.
Management indicated that its ongoing restructuring initiative will likely generate pre-tax expenses of approximately $250 million throughout the current fiscal year.
Pending Kimberly-Clark Transaction Influences Future Projections
Kenvue opted not to provide forward-looking guidance given the ongoing $40 billion merger agreement with Kimberly-Clark, anticipated to finalize during the latter half of 2026, pending international regulatory clearances.
Kimberly-Clark shares appreciated roughly 2.05% during the session, with market participants viewing the earnings report positively for the acquiring company.
RBC Capital Markets equity analyst Nik Modi characterized the quarterly results as positive for Kimberly-Clark, stating “Kenvue’s fundamentals seem to be stabilizing.” He emphasized that near-term equity performance will probably depend more heavily on transaction timing and legal developments rather than core operational metrics.
